1. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 24(3):421 (2015) PMID 25645727

    Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathwa...
  2. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

    World Journal of Clinical Oncology 5(5):990 (2014) PMID 25493235 PMCID PMC4259959

    About 75% of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (s...
  3. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

    World Journal of Clinical Oncology 5(5):990 (2014) PMID 25493235

    About 75% of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (s...
    PDF not found
  4. FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer.

    Clinical Nuclear Medicine 39(2):e135 (2014) PMID 24398430

    We aim to retrospectively evaluate the impact of hormone therapy (HT) on FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT. Three hundred eight patients with BC were scanned with PET/CT at 2 Italian institutions (mean time from diagnosis 4 yrs, range: 1-24 y...
  5. Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.

    Expert Opinion on Pharmacotherapy 13(15):2143 (2012) PMID 22984936

    Endocrine therapy is a fundamental component of the therapeutic repertoire for treatment of metastatic, hormone receptor-positive breast cancer. Inevitably, however, tumors develop resistance to these compounds, and overcoming this phenomenon is a key motivator of research in this field. This re...
  6. Potential of afatinib in the treatment of patients with HER2-positive breast cancer.

    Breast Cancer Targets and Therapy 4:131 (2012) PMID 24367201 PMCID PMC3846413

    In the absence of treatment, overexpression of the human epidermal growth factor receptor 2 (HER2) predicts a poor prognosis in breast cancer. In the last decade, monoclonal antibodies and small molecule tyrosine kinase inhibitors have significantly improved the outcome of HER2-positive breast c...
  7. Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

    Expert Opinion on Pharmacotherapy 12(4):549 (2011) PMID 21208143

    Pharmacological targeting of the tyrosine kinase receptor HER2 with the monoclonal antibody trastuzumab has dramatically changed the outlook of HER2-positive breast cancer patients. However, HER2 is part of a more complex biological network that, when deregulated, plays a central role in sustain...
  8. Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.

    Oncologist 16(4):534 (2011) PMID 21393343 PMCID PMC3228112